Evidence map›Paper›PMID 28205503›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2017

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.

Danuta M Skowronski, Catharine Chambers, Suzana Sabaiduc, James A Dickinson, Anne-Luise Winter, Gaston De Serres, Steven J Drews, Agatha Jassem, Jonathan B Gubbay, Hugues Charest and 4 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Danuta M SkowronskiBritish Columbia Centre for Disease Control, Vancouver, Canada.
Catharine ChambersBritish Columbia Centre for Disease Control, Vancouver, Canada.
Suzana SabaiducBritish Columbia Centre for Disease Control, Vancouver, Canada.
James A DickinsonUniversity of Calgary, Calgary, Canada.
Anne-Luise WinterPublic Health Ontario, Toronto, Canada.
Gaston De SerresInstitut National de Santé Publique du Québec (National Institute of Health of Quebec), Québec, Canada.
Steven J DrewsAlberta Provincial Laboratory, Edmonton, Canada.
Agatha JassemBritish Columbia Centre for Disease Control, Vancouver, Canada.
Jonathan B GubbayPublic Health Ontario, Toronto, Canada.
Hugues CharestInstitut National de Santé Publique du Québec (National Institute of Health of Quebec), Québec, Canada.
Robert BalshawBritish Columbia Centre for Disease Control, Vancouver, Canada.
Nathalie BastienNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Yan LiNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Mel KrajdenBritish Columbia Centre for Disease Control, Vancouver, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18-59%) overall, with variation by province. Interim virological and VE findings reported here warrant further investigation to inform potential vaccine reformulation.

Indexed as

Vaccine PotencyAdolescentAdultAgedCanadaCase-Control StudiesChildChild, PreschoolFemaleHemagglutination Inhibition TestsHumansInfantInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesMiddle AgedInfluenza Vaccineseffectivenessinfluenzainfluenza-like illness - ILIinfluenza virusvaccine-preventable diseasesvaccines and immunisation

Identifiers

PMID28205503
PMCPMC5316907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.